aprepitant beta 80 mg + 125 mg harde capsules
betapharm arzneimittel gmbh kobelweg 95 d-86156 augsburg (duitsland) - aprepitant ; aprepitant - capsule, hard - ammonia (e 527) ; cellulose, microkristallijn (e 460) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; natriumlaurilsulfaat (e 487) ; poloxameer 407 ; propyleenglycol (e 1520) ; saccharose ; schellak glaze, gedeeltelijk veresterd ; titaandioxide (e 171) ; zwarte inkt - aprepitant
aprepitant beta 80 mg harde capsules
betapharm arzneimittel gmbh kobelweg 95 d-86156 augsburg (duitsland) - aprepitant - capsule, hard - ammonia (e 527) ; cellulose, microkristallijn (e 460) ; gelatine (e 441) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide zwart (e 172) ; natriumlaurilsulfaat (e 487) ; poloxameer 407 ; propyleenglycol (e 1520) ; saccharose ; schellak glaze, gedeeltelijk veresterd ; titaandioxide (e 171) ; zwarte inkt - aprepitant
brexine 20 mg tabl.
chiesi sa-nv - piroxicam-bèta-cyclodextrine complex 191,2 mg - eq. piroxicam 20 mg - tablet - 20 mg - piroxicam-bèta-cyclodextrine complex 191.2 mg - piroxicam
brexine dryfiz 20 mg bruistabl.
chiesi sa-nv - piroxicam-bèta-cyclodextrine complex 191,2 mg - eq. piroxicam 20 mg - bruistablet - 20 mg - piroxicam-bèta-cyclodextrine complex 191.2 mg - piroxicam
venoruton 2 % gel
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 2 g/100 g - gel - 2 % - hydroxyethyl-o-(bèta-)-rutoside 20 mg/g - hidrosmin
venoruton 1000 mg sachet
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - poeder voor oraal gebruik - 1000 mg - hydroxyethyl-o-(bèta-)-rutoside 1000 mg - troxerutin, combinations
venoruton forte 500 mg tabl.
eg sa-nv - hydroxyethyl-o-(bèta-)-rutoside 500 mg - tablet - 500 mg - hydroxyethyl-o-(bèta-)-rutoside 500 mg - troxerutin, combinations
reblozyl
bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andere antianemic voorbereidingen - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.
carofertin 10 mg/ml, emulsie voor injectie voor runderen en varkens
vmd n.v. - betacaroteen (e 160a (ii)) - emulsie voor injectie - betacaroteen (e 160a (ii)) 10 mg/ml, - vitamin a, plain - runderen; varkens
betaserc 16 mg tablet
pi pharma - betahistinedihydrochloride - tablet - 16 mg - betahistinedihydrochloride 16 mg - betahistine